Ahmed F. Mohamed

2 papers in the library · 5 citations · publishing 2025-2026

Papers

Sigma-1 Receptor Activation by Fluvoxamine Ameliorates ER Stress, Synaptic Dysfunction and Behavioral Deficits in a Ketamine Model of Schizophrenia.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology July 25, 2025 Mariam K Ahmed, Kareem Abdou, Weam W Ibrahim et al. 5 citations

Fluvoxamine, a sigma-1 receptor agonist, alleviated learning deficits, cognitive inflexibility, and social impairments in a rat model of schizophrenia induced by ketamine. It restored nNOS/PSD-95/NMDAR signaling, increased parvalbumin and GAD67 levels in the prefrontal cortex, and reduced markers of unfolded protein response (IRE-1, PERK, ATF-6), indicating relief from ER stress. Fluvoxamine also lowered inflammatory markers (Iba-1, TNF-α) and apoptotic markers (Bax, caspase-12) while increasing Bcl-2, and reduced neuronal damage. Co-administration of the sigma-1 receptor blocker NE100 diminished these effects, implicating sigma-1 receptor signaling as a therapeutic target for schizophrenia.

DOI: 10.1007/s11481-025-10231-4 Full text Chaperones Er stress Misfolded proteins Psychiatric disorders schizophrenia +4

Targeting beta-2 adrenergic receptor attenuates schizophrenia-like behavioral effects induced by ketamine in mice: cAMP/PKA/BDNF-PEA-3 and RIM-1α signaling pathways involvement

Saudi Pharmaceutical Journal April 1, 2026 Mohammed M. Heikal, Ahmed F. Mohamed, Nora O. Abdel Rasheed et al.

Formoterol, a drug typically used for asthma, showed neuroprotective effects in a mouse model of schizophrenia-like behaviors induced by ketamine. It reduced anxiety, improved social interaction, and reversed anhedonia, while also restoring neurotransmitter balance and enhancing learning and memory. The drug reduced neuroinflammation and oxidative stress, and modulated synaptic plasticity by boosting the cAMP/PKA/BDNF signaling pathway, which increased expression of genes and proteins involved in synaptic function, including glutamate receptor subunits and regulators like PSD-95 and synaptophysin. These effects were blocked by a PKA inhibitor, confirming the pathway's role. Formoterol may be a promising candidate for treating synaptic dysfunction in schizophrenia.

DOI: 10.1007/s44446-026-00079-x Medicine